Discover
ENGOT Network

The European Network for Gynaecological Oncological Trial groups (ENGOT) consists of 21 European trial groups that perform cooperative clinical trials. ENGOT's mission is to bring the best treatment to gynaecological cancer patients through the best science.

Read More
- For Patients
Discover the ENGOT Network.

Read More
Clinical Trials
ENGOT Network

The European Network for Gynaecological Oncological Trial groups (ENGOT) consists of 21 European trial groups that perform cooperative clinical trials. ENGOT's mission is to bring the best treatment to gynaecological cancer patients through the best science.

Read More
- Current Clinical Trials
  
  Ovarian
  
  Endometrial
  
  Cervical
  
  Vulvar
  
  Basket
  
  Translational Research
- Published Trials
Discover the ENGOT Network.

Read More
Education
ENGOT Network

The European Network for Gynaecological Oncological Trial groups (ENGOT) consists of 21 European trial groups that perform cooperative clinical trials. ENGOT's mission is to bring the best treatment to gynaecological cancer patients through the best science.

Read More
Discover the ENGOT Network.

Read More

myENGOT

The European Network of Gynaecological Oncological Trial groups

ENGOT is a research network of the European Society of Gynaecological Oncology (ESGO), consists of 21 trial groups from 25 European countries that perform cooperative clinical trials. >>Read More

ESGO 2019 Congress

Get ready for the 21st Biennial International Meeting of the European Society of Gynaecological Oncology, November 2-5, 2019 in Athens, Greece.
>>Read More

FOR PATIENTS

Find Out More!

GCA Workshops

Find out more!

PUBLICATIONS

Discover it Now!

ENGOT Mission

ENGOT is a platform that guarantees that the European spirit and culture is incorporated into the medical progress in gynaecological oncology, and that all European patients and countries can participate in an active way in clinical research and progress.

The ultimate goal is to bring the best treatment to gynecological cancer patients through the best science, and enabling every patient in every European country to access a clinical trial.